Fibroblast growth factor-2 in hyperplastic pituitaries of D2R knockout female mice

Mostrar otras versiones (1)

Dopamine D2 receptor (D2R) knockout (KO) female mice develop chronic hyperprolactinemia and pituitary hyperplasia. Our objective was to study the expression of the mitogen fibroblast growth factor (FGF2) and its receptor, FGFR1, comparatively in pituitaries from KO and wild-type (WT) female mice. We...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Cristina, C.
Otros Autores: Díaz-Torga, G., Góngora, A., Guida, M.C, Perez-Millán, M.I, Baldi, A., Becu-Villalobos, D.
Formato: Capítulo de libro
Lenguaje:Inglés
Publicado: 2007
Materias:
HYPERPLASIA
Acceso en línea:Registro en Scopus
DOI
Handle
Registro en la Biblioteca Digital
Aporte de:Registro referencial: Solicitar el recurso aquí
Biblioteca Central Dr. Luis F. Leloir (FCEN) de Universidad de Buenos Aires
LEADER 19709caa a22018377a 4500
001 PAPER-22569
003 AR-BaUEN
005 20230518205408.0
008 190411s2007 xx ||||fo|||| 00| 0 eng|d
024 7 |2 scopus  |a 2-s2.0-36148950965 
024 7 |2 cas  |a prolactin, 12585-34-1, 50647-00-2, 9002-62-4; Extracellular Signal-Regulated MAP Kinases, EC 2.7.1.37; Fgfr1 protein, mouse, EC 2.7.1.112; Fibroblast Growth Factor 2, 103107-01-3; Prolactin, 9002-62-4; Receptor, Fibroblast Growth Factor, Type 1, EC 2.7.1.112; Receptors, Dopamine D2 
040 |a Scopus  |b spa  |c AR-BaUEN  |d AR-BaUEN 
030 |a AJPMD 
100 1 |a Cristina, C. 
245 1 0 |a Fibroblast growth factor-2 in hyperplastic pituitaries of D2R knockout female mice 
260 |c 2007 
270 1 0 |m Becu-Villalobos, D.; Instituto de Biología Y Medicina Experimental, CONICET, V. Obligado 2490, (1428) Buenos Aires, Argentina; email: dbecu@dna.uba.ar 
506 |2 openaire  |e Política editorial 
504 |a Abbass, S.A., Asa, S.L., Ezzat, S., Altered expression of fibroblast growth factor receptors in human pituitary adenomas (1997) J Clin Endocrinol Metab, 82, pp. 1160-1166 
504 |a Arnaud, E., Touriol, C., Boutonnet, C., Gensac, M.C., Vagner, S., Prats, H., Prats, A.C., A new 34-kilodalton isoform of human fibroblast growth factor 2 is cap dependently synthesized by using a non-AUG start codon and behaves as a survival factor (1999) Mol Cell Biol, 19, pp. 505-514 
504 |a Asa, S.L., Kelly, M.A., Grandy, D.K., Low, M.J., Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice (1999) Endocrinology, 140, pp. 5348-5355 
504 |a Baird, A., Mormede, P., Ying, S.Y., Wehrenberg, W.B., Ueno, N., Ling, N., Guillemin, R., A nonmitogenic pituitary function of fibroblast growth factor: Regulation of thyrotropin and prolactin secretion (1985) Proc Natl Acad Sci USA, 82, pp. 5545-5549 
504 |a Bikfalvi, A., Klein, S., Pintucci, G., Rifkin, D.B., Biological roles of fibroblast growth factor-2 (1997) Endocr Rev, 18, pp. 26-45 
504 |a Black, E.G., Logan, A., Davis, J.R., Sheppard, M.C., Basic fibroblast growth factor affects DNA synthesis and cell function and activates multiple signalling pathways in rat thyroid FRTL-5 and pituitary GH3 cells (1990) J Endocrinol, 127, pp. 39-46 
504 |a Choi, J., Ko, M.K., Kay, E.P., Subcellular localization of the expressed 18 kDa FGF-2 isoform in corneal endothelial cells (2000) Mol Vis, 6, pp. 222-231 
504 |a Cristina, C., Diaz-Torga, G., Baldi, A., Gongora, A., Rubinstein, M., Low, M.J., Becu-Villalobos, D., Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice (2005) Endocrinology, 146, pp. 2952-2962 
504 |a Cristina, C., Diaz-Torga, G.S., Goya, R.G., Kakar, S.S., Perez-Millan, M.I., Passos, V.Q., Gianella-Neto, D., Becu-Villalobos, D., PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes (2007) Mol Cancer, 6, p. 4 
504 |a Cristina, C., García-Tornadú, I., Diaz-Torga, G., Rubinstein, M., Low, M.J., Becu-Villalobos, D., The dopaminergic D2 receptor knockout mouse: An animal model of prolactinoma (2006) Front Horm Res, 35, pp. 50-63 
504 |a Delrieu, I., The high molecular weight isoforms of basic fibroblast growth factor (FGF-2): An insight into an intracrine mechanism (2000) FEBS Lett, 468, pp. 6-10 
504 |a Diaz-Torga, G., Feierstein, C., Libertun, C., Gelman, D., Kelly, M.A., Low, M.J., Rubinstein, M., Becu-Villalobos, D., Disruption of the D2 dopamine receptor alters GH and IGF-I secretion and causes dwarfism in male mice (2002) Endocrinology, 143, pp. 1270-1279 
504 |a Ezzat, S., Smyth, H.S., Ramyar, L., Asa, S.L., Heterogeneous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas (1995) J Clin Endocrinol Metab, 80, pp. 878-884 
504 |a Ezzat, S., Zheng, L., Asa, S.L., Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: A mechanism underlying pituitary neoplasia (2004) Mol Endocrinol, 18, pp. 2543-2552 
504 |a Ferrara, N., Schweigerer, L., Neufeld, G., Mitchell, R., Gospodarowicz, D., Pituitary follicular cells produce basic fibroblast growth factor (1987) Proc Natl Acad Sci USA, 84, pp. 5773-5777 
504 |a Florkiewicz, R.Z., Baird, A., Gonzalez, A.M., Multiple forms of bFGF: Differential nuclear and cell surface localization (1991) Growth Factors, 4, pp. 265-275 
504 |a Florkiewicz, R.Z., Majack, R.A., Buechler, R.D., Florkiewicz, E., Quantitative export of FGF-2 occurs through an alternative, energy-dependent, non-ER/Golgi pathway (1995) J Cell Physiol, 162, pp. 388-399 
504 |a Fukui, S., Otani, N., Nawashiro, H., Yano, A., Nomura, N., Miyazawa, T., Ohnuki, A., Shima, K., Subcellular localization of basic fibroblast growth factor and fibroblast growth factor receptor 1 in pituitary adenomas (2002) Brain Tumor Pathol, 19, pp. 23-29 
504 |a Fumagalli, F., Bedogni, F., Maragnoli, M.E., Gennarelli, M., Perez, J., Racagni, G., Riva, M.A., Dopaminergic D2 receptor activation modulates FGF-2 gene expression in rat prefrontal cortex and hippocampus (2003) J Neurosci Res, 74, pp. 74-80 
504 |a Garcia-Tornadu, I., Rubinstein, M., Gaylinn, B.D., Hill, D., Arany, E., Low, M.J., Diaz-Torga, G., Becu-Villalobos, D., GH in the dwarf dopaminergic D2 receptor knockout mouse: Somatotrope population, GH release, and responsiveness to GH-releasing factors and somatostatin (2006) J Endocrinol, 190, pp. 611-619 
504 |a Gonzalez, A.M., Logan, A., Ying, W., Lappi, D.A., Berry, M., Baird, A., Fibroblast growth factor in the hypothalamic-pituitary axis: Differential expression of fibroblast growth factor-2 and a high affinity receptor (1994) Endocrinology, 134, pp. 2289-2297 
504 |a Gonzalez Iglesias, A., Diaz-Torga, G., Piroli, G., Achaval-Zaia, R., De Nicola, A.F., Libertun, C., Becu-Villalobos, D., Bromocriptine restores Angiotensin II response in pituitary hyperplasia (2000) Mol Cell Endocrinol, 165, pp. 67-74 
504 |a Gospodarowicz, D., Cheng, J., Lui, G.M., Baird, A., Bohlen, P., Isolation of brain fibroblast growth factor by heparin-Sepharose affinity chromatography: Identity with pituitary fibroblast growth factor (1984) Proc Natl Acad Sci USA, 81, pp. 6963-6967 
504 |a Gospodarowicz, D., Ferrara, N., Schweigerer, L., Neufeld, G., Characterization and biological functions of fibroblast growth factors (1987) Endocr Rev, 8, pp. 95-114 
504 |a Graeven, U., Fiedler, W., Karpinski, S., Ergun, S., Kilic, N., Rodeck, U., Schmiegel, W., Hossfeld, D.K., Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR (1999) J Cancer Res Clin Oncol, 125, pp. 621-629 
504 |a Heaney, A.P., Fernando, M., Melmed, S., Functional role of estrogen in pituitary tumor pathogenesis (2002) J Clin Invest, 109, pp. 277-283 
504 |a Heaney, A.P., Horwitz, G.A., Wang, Z., Singson, R., Melmed, S., Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis (1999) Nat Med, 5, pp. 1317-1321 
504 |a Iaccarino, C., Samad, T.A., Mathis, C., Kercret, H., Picetti, R., Borrelli, E., Control of lactotrop proliferation by dopamine: Essential role of signaling through D2 receptors and ERKs (2002) Proc Natl Acad Sci USA, 99, pp. 14530-14535 
504 |a Ishikawa, H., Heaney, A.P., Yu, R., Horwitz, G.A., Melmed, S., Human pituitary tumor-transforming gene induces angiogenesis (2001) J Clin Endocrinol Metab, 86, pp. 867-874 
504 |a Joy, A., Moffett, J., Neary, K., Mordechai, E., Stachowiak, E.K., Coons, S., Rankin-Shapiro, J., Stachowiak, M.K., Nuclear accumulation of FGF-2 is associated with proliferation of human astrocytes and glioma cells (1997) Oncogene, 14, pp. 171-183 
504 |a Kelly, M.A., Rubinstein, M., Asa, S.L., Zhang, G., Saez, C., Bunzow, J.R., Allen, R.G., Low, M.J., Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice (1997) Neuron, 19, pp. 103-113 
504 |a Keresztes, M., Boonstra, J., Import(ance) of growth factors in(to) the nucleus (1999) J Cell Biol, 145, pp. 421-424 
504 |a Kuchenbauer, F., Theodoropoulou, M., Hopfner, U., Stalla, J., Renner, U., Tonn, J.C., Low, M.J., Paez-Pereda, M., Laminin inhibits lactotroph proliferation and is reduced in early prolactinoma development (2003) Mol Cell Endocrinol, 207, pp. 13-20 
504 |a Larson, G.H., Koos, R.D., Sortino, M.A., Wise, P.M., Acute effect of basic fibroblast growth factor on secretion of prolactin as assessed by the reverse hemolytic plaque assay (1990) Endocrinology, 126, pp. 927-932 
504 |a Li, A., Guo, H., Luo, X., Sheng, J., Yang, S., Yin, Y., Zhou, J., Zhou, J., Apomorphine-induced activation of dopamine receptors modulates FGF-2 expression in astrocytic cultures and promotes survival of dopaminergic neurons (2006) FASEB J, 20, pp. 1263-1265 
504 |a Li, Y., Koga, M., Kasayama, S., Matsumoto, K., Arita, N., Hayakawa, T., Sato, B., Identification and characterization of high molecular weight forms of basic fibroblast growth factor in human pituitary adenomas (1992) J Clin Endocrinol Metab, 75, pp. 1436-1441 
504 |a Marin, F., Boya, J., Immunocytochemical localization of basic fibroblast growth factor in the human pituitary gland (1995) Neuroendocrinology, 62, pp. 523-529 
504 |a McCabe, C.J., Khaira, J.S., Boelaert, K., Heaney, A.P., Tannahill, L.A., Hussain, S., Mitchell, R., Gittoes, N.J., Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: Relationships to clinical tumour behaviour (2003) Clin Endocrinol (Oxf), 58, pp. 141-150 
504 |a Meloche, S., Seuwen, K., Pages, G., Pouyssegur, J., Biphasic and synergistic activation of p44mapk (ERK1) by growth factors: Correlation between late phase activation and mitogenicity (1992) Mol Endocrinol, 6, pp. 845-854 
504 |a Mormede, P., Baird, A., Estrogens, cyclic adenosine 3-′,5′-monophosphate, and phorbol esters modulate the prolactin response of GH3 cells to basic fibroblast growth factor (1988) Endocrinology, 122, pp. 2265-2271 
504 |a Moscatelli, D., High and low affinity binding sites for basic fibroblast growth factor on cultured cells: Absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells (1987) J Cell Physiol, 131, pp. 123-130 
504 |a Moscatelli, D., Autocrine downregulation of fibroblast growth factor receptors in F9 teratocarcinoma cells (1994) J Cell Physiol, 160, pp. 555-562 
504 |a Mukdsi, J.H., De Paul, A.L., Petiti, J.P., Gutierrez, S., Aoki, A., Torres, A.I., Pattern of FGF-2 isoform expression correlated with its biological action in experimental prolactinomas (2006) Acta Neuropathol (Berl), 112, pp. 491-501 
504 |a Okada-Ban, M., Thiery, J.P., Jouanneau, J., Fibroblast growth factor-2 (2000) Int J Biochem Cell Biol, 32, pp. 263-267 
504 |a Piroli, G., Torres, A., Grillo, C., Lux-Lantos, V., Aoki, A., De Nicola, A.F., Mechanisms in progestin antagonism of pituitary tumorigenesis (1998) J Steroid Biochem Mol Biol, 64, pp. 59-67 
504 |a Presta, M., Dell'Era, P., Mitola, S., Moroni, E., Ronca, R., Rusnati, M., Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis (2005) Cytokine Growth Factor Rev, 16, pp. 159-178 
504 |a Renko, M., Quarto, N., Morimoto, T., Rifkin, D.B., Nuclear and cytoplasmic localization of different basic fibroblast growth factor species (1990) J Cell Physiol, 144, pp. 108-114 
504 |a Roceri, M., Molteni, R., Fumagalli, F., Racagni, G., Gennarelli, M., Corsini, G., Maggio, R., Riva, M., Stimulatory role of dopamine on fibroblast growth factor-2 expression in rat striatum (2001) J Neurochem, 76, pp. 990-997 
504 |a Saiardi, A., Bozzi, Y., Baik, J.H., Borrelli, E., Antiproliferative role of dopamine: Loss of D2 receptors causes hormonal dysfunction and pituitary hyperplasia (1997) Neuron, 19, pp. 115-126 
504 |a Schechter, J., Weiner, R., Changes in basic fibroblast growth factor coincident with estradiol-induced hyperplasia of the anterior pituitaries of Fischer 344 and Sprague-Dawley rats (1991) Endocrinology, 129, pp. 2400-2408 
504 |a Silverlight, J.J., Prysor-Jones, R.A., Jenkins, J.S., Basic fibroblast growth factor in human pituitary tumors (1990) Clin Endocrinol (Oxf), 32, pp. 669-676 
504 |a Straume, O., Akslen, L.A., Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/ EphA2 on melanoma progression (2002) Am J Pathol, 160, pp. 1009-1019 
504 |a Strauss, O., Mergler, S., Wiederholt, M., Regulation of L-type calcium channels by protein tyrosine kinase and protein kinase C in cultured rat and human retinal pigment epithelial cells (1997) FASEB J, 11, pp. 859-867 
504 |a Sulpice, E., Bryckaert, M., Lacour, J., Contreres, J.O., Tobelem, G., Platelet factor 4 inhibits FGF2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not by the phosphatidyl-inositol 3-kinase pathway (2002) Blood, 100, pp. 3087-3094 
504 |a Tfelt-Hansen, J., Kanuparthi, D., Chattopadhyay, N., The emerging role of pituitary tumor transforming gene in tumorigenesis (2006) Clin Med Res, 4, pp. 130-137 
504 |a Tooyama, I., Kawamata, T., Walker, D., Yamada, T., Hanai, K., Kimura, H., Iwane, M., McGeer, P.L., Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease (1993) Neurology, 43, pp. 372-376 
504 |a Zhang, X., Horwitz, G.A., Prezant, T.R., Valentini, A., Nakashima, M., Bronstein, M.D., Melmed, S., Structure, expression, and function of human pituitary tumor-transforming gene (PTTG) (1999) Mol Endocrinol, 13, pp. 156-166 
520 3 |a Dopamine D2 receptor (D2R) knockout (KO) female mice develop chronic hyperprolactinemia and pituitary hyperplasia. Our objective was to study the expression of the mitogen fibroblast growth factor (FGF2) and its receptor, FGFR1, comparatively in pituitaries from KO and wild-type (WT) female mice. We also evaluated FGF2 subcellular localization and FGF2 effects on pituitary function. FGF2-induced prolactin release showed a similar response pattern in both genotypes, even though basal and FGF2-stimulated release was higher in KO. FGF2 stimulated pituitary cellular proliferation (MTS assay and [ 3H]thymidine incorporation), with no differences between genotypes. FGF2 concentration (measured by ELISA) in whole pituitaries or cultured cells was lower in KO (P < 0.00001 and 0.00014). Immunofluorescence histochemistry showed less FGF2 in pituitaries from KO females and revealed a distinct FGF2 localization pattern between genotypes, being predominantly nuclear in KO and cytosolic in WT pituitaries. Finally, FGF2 could not be detected in the conditioned media from pituitary cultures of both genotypes. FGFR1 levels (Western blot and immunohistochemistry) were higher in pituitaries of KO. Basal concentration of phosphorylated ERKs was lower in KO cells (P = 0.018). However, when stimulated with FGF2, a significantly higher increment of ERK phosphorylation was evidenced in KO cells (P ≤ 0.02). We conclude that disruption of the D2R caused an overall decrease in pituitary FGF2 levels, with an increased distribution in the nucleus, and increased FGFR1 levels. These results are important in the search for reliable prognostic indicators for patients with pituitary dopamine-resistant prolactinomas, which will make tumor-specific therapy possible. Copyright © 2007 the American Physiological Society.  |l eng 
593 |a Instituto de Biologia Y Medicina Experimental, Consejo Nacional de Investigaciones Científicas Y Técnicas-Argentina, Buenos Aires, Argentina 
593 |a Instituto de Biología Y Medicina Experimental, CONICET, V. Obligado 2490, (1428) Buenos Aires, Argentina 
690 1 0 |a DOPAMINERGIC D2 RECEPTOR 
690 1 0 |a EXTRACELLULAR SIGNAL-REGULATED KINASE PHOSPHORYLATION 
690 1 0 |a FIBROBLAST GROWTH FACTOR RECEPTOR-1 
690 1 0 |a IMMUNOHISTOCHEMISTRY 
690 1 0 |a PROLACTIN 
690 1 0 |a DOPAMINE 2 RECEPTOR 
690 1 0 |a FIBROBLAST GROWTH FACTOR 2 
690 1 0 |a PROLACTIN 
690 1 0 |a ANIMAL CELL 
690 1 0 |a ANIMAL CELL CULTURE 
690 1 0 |a ANIMAL EXPERIMENT 
690 1 0 |a ANIMAL MODEL 
690 1 0 |a ANIMAL TISSUE 
690 1 0 |a ARTICLE 
690 1 0 |a CELL ASSAY 
690 1 0 |a CELL PROLIFERATION 
690 1 0 |a CELLULAR DISTRIBUTION 
690 1 0 |a CHRONIC DISEASE 
690 1 0 |a CONCENTRATION (PARAMETERS) 
690 1 0 |a CONTROLLED STUDY 
690 1 0 |a CYTOSOL 
690 1 0 |a DNA SYNTHESIS 
690 1 0 |a ENZYME LINKED IMMUNOSORBENT ASSAY 
690 1 0 |a ENZYME PHOSPHORYLATION 
690 1 0 |a FEMALE 
690 1 0 |a GENOTYPE 
690 1 0 |a HYPERPITUITARISM 
690 1 0 |a HYPERPROLACTINEMIA 
690 1 0 |a HYPOPHYSIS FUNCTION 
690 1 0 |a IMMUNOFLUORESCENCE 
690 1 0 |a IMMUNOHISTOCHEMISTRY 
690 1 0 |a KNOCKOUT MOUSE 
690 1 0 |a MOUSE 
690 1 0 |a NONHUMAN 
690 1 0 |a PRIORITY JOURNAL 
690 1 0 |a PROGNOSIS 
690 1 0 |a PROLACTIN RELEASE 
690 1 0 |a PROLACTINOMA 
690 1 0 |a PROTEIN LOCALIZATION 
690 1 0 |a PROTEIN SECRETION 
690 1 0 |a RELIABILITY 
690 1 0 |a SPECIES COMPARISON 
690 1 0 |a WESTERN BLOTTING 
690 1 0 |a WILD TYPE 
690 1 0 |a ANIMALS 
690 1 0 |a BLOTTING, WESTERN 
690 1 0 |a CELL GROWTH PROCESSES 
690 1 0 |a ENZYME-LINKED IMMUNOSORBENT ASSAY 
690 1 0 |a EXTRACELLULAR SIGNAL-REGULATED MAP KINASES 
690 1 0 |a FEMALE 
690 1 0 |a FIBROBLAST GROWTH FACTOR 2 
690 1 0 |a IMMUNOHISTOCHEMISTRY 
690 1 0 |a MICE 
690 1 0 |a MICE, INBRED C57BL 
690 1 0 |a MICE, KNOCKOUT 
690 1 0 |a MICROSCOPY, CONFOCAL 
690 1 0 |a MICROSCOPY, FLUORESCENCE 
690 1 0 |a PHOSPHORYLATION 
690 1 0 |a PITUITARY GLAND, ANTERIOR 
690 1 0 |a PROLACTIN 
690 1 0 |a PROLACTINOMA 
690 1 0 |a RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1 
690 1 0 |a RECEPTORS, DOPAMINE D2 
651 4 |a HYPERPLASIA 
700 1 |a Díaz-Torga, G. 
700 1 |a Góngora, A. 
700 1 |a Guida, M.C. 
700 1 |a Perez-Millán, M.I. 
700 1 |a Baldi, A. 
700 1 |a Becu-Villalobos, D. 
773 0 |d 2007  |g v. 293  |h pp. E1341-E1351  |k n. 5  |p Am. J. Physiol. Endocrinol. Metab.  |x 01931849  |t American Journal of Physiology - Endocrinology and Metabolism 
856 4 1 |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-36148950965&doi=10.1152%2fajpendo.00260.2007&partnerID=40&md5=e570758ef74153469741fb4caa973e30  |y Registro en Scopus 
856 4 0 |u https://doi.org/10.1152/ajpendo.00260.2007  |y DOI 
856 4 0 |u https://hdl.handle.net/20.500.12110/paper_01931849_v293_n5_pE1341_Cristina  |y Handle 
856 4 0 |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_01931849_v293_n5_pE1341_Cristina  |y Registro en la Biblioteca Digital 
961 |a paper_01931849_v293_n5_pE1341_Cristina  |b paper  |c PE 
962 |a info:eu-repo/semantics/article  |a info:ar-repo/semantics/artículo  |b info:eu-repo/semantics/publishedVersion 
999 |c 83522 

Ejemplares similares